Modiquest offers contract research on the generation of animal and human recombinant monoclonal antibodies

ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). We use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services. contract research, technology patents, licenses, recombinant antibody services, phage display services, antibody based activity assay for peptidyl arginin deiminases (ABAP), collagen antibody induced arthritis animal model (CAIA), generation of stable recombinant antibody producing cell lines, mouse and human peptidyl arginin deiminase enzymes, proprietary human and mouse antibodies for proteomics and diagnostics, human autoantigens, apoptotic cleavage product, protein, hU1-70K, hU1-C, hJo-1, hRpp20, hRrp4, sdab, scfv, fab, pad, cancer, multiple sclerosis, rheumatoid arthritis, Animal model, Anti Citrulline Peptide Antibodies, Antibodies, Antibody, Antibody expression, anti-CCP, Antigen Specific B-cell Selection, arthritis, B-cell, B-cell culture, B-cell selection, Biotechnology, CAIA, CCP, CCP Antibodies, chicken, Collagen Antibody Induced Arthritis Animal Model, Contract Research, CRO, gene synthesis, Generation of Stable Recombinant Antibody Producing Cell Line, llama, mouse, neo epitope, Phage Display, Post translational Protein Modification, Proprietary Antibodies, Rabbit, Rare Antibody Specificities, ecombinant (Human) Auto-Antibodies, recombinant antibodies, recombinant antibody, Recombinant antibody cloning, Recombinant Antibody Cloning and Expression, Recombinant antibody expression,Recombinant Chimeric Antibodies, Recombinant Human Antibodies, Recombinant Mouse antibodies. stable cell line <span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"> <p style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="center"> </p> <table border="0" cellspacing="1" cellpadding="1" width="100%"> <tbody> <tr> <td> <div align="center"><font face="Arial"> </font></div> </td> </tr> </tbody> </table> <p> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 0pt" class="MsoNormal"> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 0pt" class="MsoNormal"><font face="Times New Roman"><span style="COLOR: black; FONT-SIZE: 11pt; mso-ansi-language: EN-GB" lang="EN-GB"><font size="2"></font> <div><font size="3">ModiQuest develops and commercializes novel proprietary therapeutic and diagnostic antibodies.</font> </div> <div> </div> <div>ModiQuest applies innovative technologies including differential proteomics in the identification of disease related protein modifications. ModiQuest uses automated high-throughput B-cell selection, highly efficient electrofusion methods, and recombinant antibody technology for the generation of corresponding diagnostic and/or therapeutic monoclonal antibodies. </div> <div> </div> <div>Modiquest’s sister company <a title="ModiQuest Research CRO website" href="http://www.modiquestresearch.com/website/" target="_blank">Modiquest Research</a> provides contract research in antibody discovery, development and  production. </div> <p style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 0pt" class="MsoNormal"> </p> </span></font></p> <p> </p> <p> </p> <p> </p> <p> </p> <p style="TEXT-ALIGN: justify; MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="center"> </p> </span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"></span><p><span lang="EN-GB" style="FONT-SIZE: 8pt; mso-ansi-language: EN-GB; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt"><span lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA"><font size="2"><span lang="EN-GB" style="mso-ansi-language: EN-GB"> <p><font face="Times New Roman" size="3"><b style="mso-bidi-font-weight: normal"><span lang="EN-GB" style="FONT-SIZE: 11pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><font size="3">Hybridoma Production Protocol<br/> </font></span></b><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> <b style="mso-bidi-font-weight: normal">Phase One: Immunization (€ 1000, approximately 60 days)</b></span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <br/> <br/> </span> <ul style="MARGIN-TOP: 0cm" type="disc"> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The monoclonal antibody protocol starts with the primary immunization of three BALB/c mice with the, by the client provided, purified antigen<sup>1</sup> emulsified with Complete Freund’s Adjuvant (CFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 14 days, the mice receive a second injection of the antigen with Incomplete Freund’s Adjuvant (IFA). </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 28 days, the mice receive a third injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 42 days, the mice receive a fourth injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The first blood sample is obtained 7 days after the fourth injection </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The polyclonal serum samples are screened by ELISA to determine the comparative titres of antigen-specific antibody. (Alternatively, the serum samples can be shipped<sup>2</sup> to the client for screening with a different assay, or ModiQuest can perform customized assays according to the clients’ specifications<sup>3</sup>)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The mouse with the best response receives a pre-fusion boost and is sacrificed for a fusion. Alternatively another round of immunizations and a second bleed<sup>4</sup> can be performed on all mice. Following a second serum assay the client decides whether the best responder mouse is selected for a fusion, or the entire cage of mice is terminated.</span> </li> </ul> <span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><font color="#800080">Payment for <b style="mso-bidi-font-weight: normal">Phase One</b> should be received before the project is initiated. <br/> </font><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> All shipments from ModiQuest will be shipped on dry ice. The fee for this service will be charged to the client.<br/> <br/> </span></p> </span> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><b style="mso-bidi-font-weight: normal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> Phase Two: Fusion (€ 2500, approximately 5 weeks) <br/> <br/> </span></b></p> <ul style="MARGIN-TOP: 0cm" type="disc"> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Three days after the pre-fusion boost, the best responder mouse is anesthetized and terminated by exsanguination and the lymphocytes are isolated from the spleen. </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The washed lymphocytes are mixed with BALB/c-derived NS1 or sp2/0 myeloma cells in fusion media and fused using an electrofusion protocol. </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Since our fusion efficiencies are very high we will store, at the clients disposal, remaining lymphocytes derived from the animal used for the fusion experiment. For fusion of NS1 myeloma cells we use 2x107 lymfocytes, for sp2/0 myeloma cells we use 2x107 lymfocytes. </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Immediately following the fusion event, hybridoma selection is performed in ten<sup>5</sup> 96-well plates containing HAT media. </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Within 14 days all surviving hybridomas are screened by an ELISA in order to isolate the primary hybridoma cultures that secrete monoclonal antibody specific for the client’s antigen. </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">In our standard protocol 5 primary cultures<sup>6</sup> (indicated by the client within 2 days of receipt of the data of the ELISA screen) are expanded for cryopreservation, and single frozen copies of each are shipped to the client along with the 4 ml of the antibody-containing culture media the cells were growing in at the time of the freeze. </span></li> </ul> <span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><font color="#800080">Payment for <strong>Phase Two</strong> should be received before the frozen copies of the primary cultures and their associated culture medias are shipped.<br/> </font>  </p> </span> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Due to the high fusion efficiency (~5000 to 10000 clones in ten 96 well plates) primary cultures should not be considered clonal. Moreover, artificially fused cells are initially genetically unstable. Such cells might expel a chromosome carrying a gene necessary for antibody production but retain their ability to divide, and can potentially overgrow antibody secreting cells.<br/> <br/> </span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><i style="mso-bidi-font-style: normal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><strong>To avoid any loss of valuable clones by overgrowing of non-producers, we immediately subclone the 5 primary cultures chosen by the client before the frozen copies are made.</strong> <br/> <br/> </span></i></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">If, in addition to the initial 5 primary clones chosen, the client wishes to expand more primary cultures, the client is expected to contact us <strong>within 2 days</strong> of receiving the ELISA screen (delays at this stage could result in the loss of an important hybridoma cell line).<br/> <br/> <br/> </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span></p> <b style="mso-bidi-font-weight: normal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Phase Three: Subcloning and Antibody Characterization </span></b> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><b style="mso-bidi-font-weight: normal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">(€ 2600, approximately 6 weeks) <br/> <br/> </span></b></p> <ul style="MARGIN-TOP: 0cm" type="disc"> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l2 level1 lfo3; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The 5 best primary cultures as determined in Phase Two are subcloned by limiting dilution into a set of 5 96-well plates.  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l2 level1 lfo3; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The client decides within the following 2 weeks which 3 of the 5 initial primary cultures in limiting dilution will be analyzed as single clones in an ELISA to determine which contain the best monoclonal antibodies specific to the client’s antigen.  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l2 level1 lfo3; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">From the best 3 primary cultures the 2 best “sisters” from one subcloned set are expanded and frozen into three copies each*, and the isotype of their monoclonal antibody is determined.  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l2 level1 lfo3; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">At the completion of Phase Three, for each primary culture subcloned the client receives 4 frozen cell line copies (2 copies of each sister subclone), the 10 ml culture medias the 2 sister subclones were growing in at the time they were frozen, and isotyping results. </span> </li> </ul> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">If the subcloning of all 3 primary cultures is successful, the client receives 12 frozen cell line copies, 6 media samples, and monoclonal antibody isotyping results for 3 cell lines.<br/> </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> Subcloning of additional primary cultures will be charged at € 800 per clone. As described above, if subcloning is successful, the client can expect 2 sister subclones, each frozen in double copies, culture media samples for each, and monoclonal antibody isotyping results. <p><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><font color="#800080">Payment for <strong>Phase Three</strong> should be received before the subcloned cell lines and their associated culture medias are shipped.</font></span></p> </span></p> <p> </p> <p> </p> </font></p> <p> </p> <p> </p> </span></font></span></span></p> <p> </p> <p> </p><p><span lang="EN-GB" style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><span style="mso-spacerun: yes"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><font size="3"><strong>ModiQuest provides polyclonal Chicken antibody services</strong></font></span>  <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong><br/> Standard polyclonal chicken antibody protocol:</strong></span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">(80 days, <span lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-US">€ 10</span>00)</span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"></span> </p> <span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"> <ul style="MARGIN-TOP: 0cm" type="disc"> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The polyclonal antibody protocol starts with obtaining a pre-immune blood sample or pre-immune eggs of two White Leghorn chicken, </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The primary immusation is performed with the, by the client provided, purified antigen<sup>1</sup> emulsified with Complete Freund’s Adjuvant (CFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 14 days, the chicken receive a second injection of the antigen with Incomplete Freund’s Adjuvant (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 28 days, the chicken receive a third injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 56 days, the chicken receive a fourth injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The first immune blood sample or immune egg is obtained 14 days after the fourth injection  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The polyclonal serum or egg yolk samples are screened by ELISA to determine the comparative titres of antigen-specific antibody. (Alternatively, the serum or egg yolk samples can be shipped<sup>2</sup> to the client for screening with a different assay, or ModiQuest can perform customized assays according to the clients’ specifications<sup>3</sup>) </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The animals with good responses are anesthetized and terminated by exsanguination or eggs are collected for a period of 2 weeks after the ELISA screening. Alternatively another round of immunizations and a second ELISA can be performed on animal sera or egg yolks. Following a second serum assay the client decides whether the animals are anesthetized and terminated by exsanguination or kept for collecting additional eggs.</span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Polyclonal serum or egg yolk (in the standard protocol a minimum of 6 immune and one preimmune eggs are included) samples are shipped to the client</span> </li> </ul> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Above immunisation protocol can be customized according to the clients specifications, and/or combined with the <a class="" href="show.php?id=6" target="_self"><u><font color="#0000ff">peptide antigen design</font></u></a> and/or <a class="" href="show.php?id=6" target="_self"><u><font color="#0000ff">affinity purification</font></u></a> protocols. Please note that IgY cannot be purified using Prot A or Prot G. </span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span> </p> <span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><font color="#800080">Payment for the <b style="mso-bidi-font-weight: normal">polyclonal rabbit antibody services </b>should be received before the project is initiated. <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> <font color="#000000">All shipments from ModiQuest will be shipped on dry ice. The fee for this service will be charged to the client.</font></span></p> </font></p> <p> </p> <p> </p> </span></span></span></span></p> <p> </p> <p> </p><div> </div> <div>All ModiQuest antibody products are commercially available via the <a href="http://www.modiquestresearch.com/shop" target="_blank">ModiQuest Research webshop</a>.  </div><p align="justify"><strong>ModiQuest </strong>has developed an efficient mix of anti-collagen antibodies for the generation of a collagen antibody induced arthritis (CAIA) mouse animal model.</p> <p align="justify">Collagen-induced arthritis is an antibody mediated disease.  Therefore, type II collagen specific antibodies can be used to induce arthritis in mice. Our mixture of type II collagen specific antibodies (2.6mg per animal) induces severe inflammation in the ankle and paws of DBA mice which resemble many aspects of arthritis. One of the biggest advantages of our monoclonal antibody-induced arthritis model is that severe arthritis is induced within 24-48 hours instead of the four weeks required to induce arthritis after immunization with type II collagen.  ModiQuest Research recommends highly susceptible DBA/1 mice. Other strains may be used, however the amount of antibody cocktail required may vary. Thus, this model is ideal for rapidly screening therapeutics for the treatment of arthritis and to study the mechanisms involved in the development of arthritis.</p> <p align="justify">These CAIA antibodies are offered to clients via ModiQuest Research. <span style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold" lang="EN-GB"><a href="http://www.modiquestresearch.nl/shop/index.php?cPath=32" target="_blank"><u><font color="#810081">Please click here to go to our online shop directly</font></u></a>. </span>Next to that under collaboration with third parties animal studies using these CAIA antibodies are offered by ModiQuest Research. For inquiries about full animal studies using the MQR-CAIA model please contact <a href="mailto:info@modiquestresearch.com?subject=CAIA%20full%20study%20inquiruies"><u><font color="#0000ff">ModiQuest Research</font></u></a> directly. For downloading a spec. sheet about the commercially available MQR-CAIA antibody model please <a href="http://www.modiquestresearch.com/website/downloads/download.php?id=42" target="_blank"><u><font color="#0000ff">click here</font></u></a>.</p> <p align="justify"> </p><p align="justify"><strong>ModiQuest</strong> uses its u<span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">nique <strong>Hi-tech facility</strong> to generate <strong>high producing</strong> primary cells and <strong>stable cell lines</strong>.</span> </p> <p align="justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"><strong>ModiQuest </strong>focusses on the g</span><span>eneration of stable, high level, antibody producing cell lines (using <strong>AMAXA Nucleofection</strong>, high throughput <strong>ClonePix technology</strong>, and optimised <strong>proprietary vector systems</strong>). </span></p> <p align="justify"><span>Various <strong>Mouse</strong> and <strong>Human</strong> isotypes as well as <strong>Chicken</strong> based recombinant (chimeric) antibody producing cell lines can be generated very efficiently. <p align="center"><img alt="" src="http://www.modiquestresearch.com/website/downloads/Image/clonepixb.JPG"/></p> <p align="justify">All antibodies can be <strong>fully optimised</strong> towards specific diagnostic or therapeutic requirements. Using both <strong>gene synthesis</strong> to create novel expression constructs and antibodies, or adaptation of the large <strong>ModiQuest expression vector</strong> range to create or optimise antibodies for their specific applications.</p> </span></p> <p> </p> <p> </p> <p> </p> <p> </p> <p align="justify"> </p><p align="justify"><strong>ModiQuest </strong>has developed a sensitive Antibody Based Assay to test for Peptidyl Arginine Deiminase (PAD) activity (ABAP). The ABAP is an Enzyme Linked-Immuno-Sorbent Assay (ELISA) for the determination of PAD enzyme activity in cell and tissue lysates. </p> <p align="justify">PAD enzymes are transcriptional co-regulators that catalyze the calcium dependent conversion of specific arginine residues present in for instance histones to citrulline.  In diseases such as multiple sclerosis and rheumatoid arthritis (RA) these PAD enzymes seem to be dysregulated. For instance in RA these enzymes become active when they exit the cell in regions of joint inflammation where they deiminate arginines in proteins such as vimentin and fibrinogen. The level of PAD activity has been correlated with RA severity. </p> <p align="justify">The ABAP test is also suitable for determining PAD activity of purified recombinant PAD enzymes used in various bioassays. </p> <p align="justify">Via ModiQuest Research this kit is commecially available. The <font color="#800000"><a href="http://www.modiquestresearch.nl/shop/index.php?cPath=31" target="_blank">MQR-ABAP</a></font> test is a powerful method to rapidly screen for PAD activity. Compared to currently used assays for PAD activity determination such as the DAMO BAEE conversion test the <font color="#800000"><a href="http://www.modiquestresearch.nl/shop/index.php?cPath=31" target="_blank">MQR-ABAP</a></font> assay is more robust, and at least 500 times more sensitive.  </p> <p align="justify">The commercial availble ABAP kit consists of: 1) 96-well plate coated with Arginine containing peptides 2) A ModiQuest Research mouse PAD enzyme for activity calibration 3) a proprietary ModiQuest Research HRP-labelled monoclonal antibody specifically binding deiminated arginines. A detalied spec. sheet for the ABAP test can be downloaded by <a href="http://www.modiquestresearch.nl/shop/files/MQ17.101-96%20_ABAP_%20MQR.pdf" target="_blank"><u><font color="#0000ff">clicking here</font></u></a> (pdf).</p><p><font size="3">ModiQuest continues its participation and support of the IOP project <a href="downloads/download.php?id=44" target="_blank">"Improving the cellular defence system by enhancing stress responses".</a></font> </p> <p>A research collaboration dedicated to the development of novel diagnostics and or therapeutics to combat age related diseases like Alzheimer`s as well as chronic inflammatory diseases.</p><p><font size="3"><strong>ModiQuest is looking for dynamic new colleagues for the following function(s):</strong></font></p> <p><strong><font size="3"></font></strong></p> <p> <table cellspacing="2" cellpadding="2" width="400" align="center" border="0"> <tbody> <tr> <td> <p><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>23-10-2008</strong></span></p> <p><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong><font size="3">Senior scientist(s)/manager(s):</font></strong></span> </p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"></span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><font size="3">Candidate(s) will head the mammalian cell line development unit and/or the recombinant antibody unit.</font></span></p> </td> </tr> <tr> <td> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><u>Requirements:</u></span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- PhD with minimum of 5 years experience in commercial mammalian tissue culture & molecular biology setting</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Focus on project management and supervision of cell culture lab and related molecular biologic approaches</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Hands on experience required in the following fields:</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- High throughput stable cell line generation (electroporation technology, automated screening)</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- FACS (sorting, cloning, analysis)</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- Process development: Upscaling, mammalian cell culture bioreactors for protein production, purification.</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- DNA cloning, vector construction, expression optimisation.</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- Antibody production</span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- Molecular cloning and optimisation of recombinant antibodies. </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Preferentially experience with recombinant antibody display and modelling technologies. </span></p> <p class="MsoNormal"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">- Antibody humanisation</span></p> </td> </tr> <tr> <td> <div><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">Outstanding command of the English language; both orally and written</span></div> </td> </tr> <tr> <td> <div><font face="Arial">Candidate is able to effectively guide the transition process from research to practical product development. </font></div> <div><font face="Arial"></font></div> <div> <pbr></pbr> <font face="Arial">You have good interpersonal and project management skills. </font></div> <div><font face="Arial"></font></div> <div><font face="Arial">You have a creative and innovative approach that can motivate and stimulate others. </font></div> <div> </div> <div><font face="Arial">You have analytical skills and are capable of keeping an overview of the diverse activities and timelines involved in your work </font></div> </td> </tr> <tr> <td> <div><font face="Arial">The salary for this full-time position is depending on experience.<br/> The post is located in Nijmegen, the Netherlands.</font></div> </td> </tr> </tbody> </table> </p><p><strong><font size="3">Welcome to project MQ2008018</font></strong></p> <p>Pleae click on file manager in upper right corner to view, up or download files to this project.</p> <p>Please make sure all files are <strong>password</strong> secured.</p> <p>For any additional questions please call or mail the <strong>Modiquest Team.</strong> Please mention or indicate the project number in your phone or email with our team.</p> <p>Phone: +31 (0)24 3614253</p> <p>E-mail: <a href="mailto:info@modiquest.com">info@modiquest.com</a></p><p><strong><font size="3">Welcome to SENTER IS PAD peptide inhibitor project</font></strong></p> <p>Pleae click on file manager in upper right corner to view, up or download files to this project.</p> <p>Please make sure all files are <strong>password</strong> secured.</p> <p>For any additional questions please call or mail the <strong>Modiquest Team.</strong> Please mention or indicate the project number in your phone or email with our team.</p> <p>Phone: +31 (0)24 3614253</p> <p>E-mail: <a href="mailto:info@modiquest.com"><u><font color="#0000ff">info@modiquest.com</font></u></a></p><div> </div> <div>In its therapeutics programme, ModiQuest focusses on the discovery of novel targets, lead generation and pre-clinical development. </div> <div> </div> <div>In particular, ModiQuest works on the development of novel therapeutics for Rheumatoid arthritis and inflammatory disorders. </div> <div> </div> <div>Currently we have two therapeutic compound families for rheumatoid arthritis in the preclinical development phase.</div> <p class="titleH1"> </p><p><strong>Novel Diagnostics</strong></p><div><strong>Additional antibody related services provided by ModiQuest</strong></div> <div> </div> <div><strong>Peptide antigen design</strong></div> <div> </div> <div>In case no purified protein product is available for use as an immunogen, but the whole or partial amino acid sequence of the protein is known, ModiQuest can perform computer analysis of the protein sequence to pinpoint key antigenic peptide sequences within the protein. </div> <div>These antigenic peptide sequences (12-24 amino acids) can be synthesized and covalently conjugated to a large protein carrier such as KLH. The conjugate is injected into laboratory animals, and the resulting antibody response will include antibodies that recognize the peptide sequence. </div> <div>Since the peptide sequences are initially chosen based on surface probability, hydrophilicity, and secondary structure characteristics there is a high probability that anti-peptide antibodies will recognize the intact native or denatured protein.</div> <div><br/> ModiQuest’ will consult with clients who require peptide antigen design. The fees associated with this service will include all necessary consultation between the client and ModiQuest, protein sequence analysis, peptide synthesis, peptide conjugation to KLH (immunogen), and peptide conjugation to BSA (test conjugate for antibody analysis and affinity purification). At the completion of the project, the client will receive any unused conjugate as well as all remaining purified peptide.</div> <div><em>Fees depend on peptide size, sequence composition, quantity, purity, and conjugation strategy required.</em></div> <div> </div> <div><font color="#800080">All fees associated with the <strong>peptide antigen design service</strong> are to be paid before the peptide synthesis is initiated.</font></div> <div> </div> <div> </div> <div><strong>Affinity purification of antibodies</strong></div> <div> </div> <div>ModiQuest performs affinity purifications of poly- and mono-clonal antibodies on Prot A, Prot G, or conjugated antigen matrixes. </div> <ul type="square"> <li>Peptide or antigen conjugation to carrier protein or affinity column, € 200. </li> </ul> <ul type="square"> <li>Affinity purification of 10-20ml animal serum on conjugated antigen column, € 450. </li> </ul> <ul type="square"> <li>Affinity purification on Prot A or Prot G column (2 ml resin) € 450. </li> </ul> <div>Affinity purification includes dialyses of the purified antibodies against PBS or client specified buffer, and concentration determination of the purified antibodies.</div> <div><br/> <font color="#800080">Payment for <strong>affinity purified antibodies </strong>should be received before the purified antibodies are shipped.</font></div><span style="FONT-SIZE: 11pt; mso-ansi-language: EN-US; mso-fareast-language: NL; mso-bidi-language: AR-SA" lang="EN-US"><span style="FONT-FAMILY: Arial; COLOR: black; mso-ansi-language: EN-US" lang="EN-US"> <div> </div> <div>ModiQuest B.V., in collaboration with <a href="http://www.modiquestresearch.nl/" target="_blank">ModiQuest Research B.V.</a>, offers contract research in antibody discovery, development and  production. Examples of our services include; </div> <ul> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Custom phage display services and advice </span></div> </li> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Highly efficient automated hybridoma generation</span></div> </li> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Generation of human antibodies via B-cell culture technology </span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"> </span></div> </li> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Protein expression and purification</span></div> </li> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Recloning of monoclonal antibody domains in bacterial vectors </span></div> </li> <li> <div style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US"></span><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">Tissue culture applications </span></div> </li> </ul> <p style="TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US" lang="EN-US">For further information please visit the <a href="http://www.modiquestresearch.com/" target="_blank">ModiQuest Research</a> website.</span></p> </span> <p> </p> <p> </p> <p> </p> </span> <p> </p> <p> </p> <p> </p> <p> </p><p align="center"> <img alt="CL1000 Bioreactor Integra" src="http://www.modiquest.com/website/downloads/Image/Cl1000.jpg" align="center" border="0"/></p> <p align="center"><span lang="EN-GB" style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><span style="mso-spacerun: yes"> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><strong><font size="3">Bioreactor CL1000 Integra Antibody Production</font></strong></span></span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span></span><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span></span> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">ModiQuest utilizes in vitro methods of antibody production as compared to the ascites fluid method, which needlessly destroys animals. <br/> </span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> At ModiQuest, we prefer to run an Integra CL1000 bioreactor for 6 weeks because this system allows the production of antibody at a reasonable price. Clients can expect a yield between 100-300 mg of their monoclonal antibody in approximately 8 weeks. Due to the variable secretion rates of hybridomas, the actual amount of antibody generated is dependent on the unique characteristics of each hybridoma. <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> One standard production run takes aproximately 8 weeks, <span lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-US">€ 2000*</span> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><strong>The standard fee for one bioreactor production run includes: </strong></span></p> </span></span></p> <p> </p> </span> <ul> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Thawing and freezing back one copy of the hybridoma.  </span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Pre-bioreactor expansion of the hybridoma</span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">One Integra CL1000 bioreactor and all the media* used in the 6 week run. We can use antibody-free FBS, or protein and serum-free medium in our bioreactor media</span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Twice-weekly media sample collections (approximate pooled yield: 100 ml) </span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Each time a sample is taken, a cell count is performed to monitor the viability of the culture  </span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">At the completion of the 6-week run, pooled bioreactor media is subjected to a 50% ammonium sulfate cut, then after centrifugation the antibody-containing pellet is resuspended in PBS (or in a buffer specified by the client). Following dialysis against PBS or client buffer, the antibody solution is aliquoted into amounts preferred by the client.</span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">A concentration assay is performed to determine the actual concentration of monoclonal antibody protein in the final solution.</span></div> </li> <li> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The processed bioreactor antibody as well as the unprocessed static flask culture media generated during the pre-bioreactor expansion is shipped to the client. </span></div> </li> </ul> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <p> *Total price depends on media required and total time of the run</p> </span></p> <p> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><font color="#800080">All costs associated with bioreactor production of monoclonal antibody are to be paid by the client before the final products are shipped.</font></span></p> </span></p> <p> </p> </span></span></p> <p> </p><span style="COLOR: black; FONT-SIZE: 11pt; mso-ansi-language: EN-GB" lang="EN-GB"><font size="2"> <div> </div> <div>ModiQuest was founded in February 2004 and is based in Nijmegen , The Netherlands. ModiQuest discovers and markets new tools, technologies and targets for (autoimmune) diagnostics and therapy. </div> <div> </div> <div>ModiQuest applies new proteomics approaches to identify disease related protein modifications and uses an automated and highly efficient electrofusion technology for the generation of monoclonal antibodies. </div> <div> </div> <div>ModiQuest is currently developing new diagnostic and therapeutic targets.Novel targets will be patented, marketed and/or out-licensed to diagnostic and or pharma companies. ModiQuest actively markets its technology and expertise for contract research applications via its sister company <a href="http://www.modiquestresearch.com/" target="_blank">ModiQuest Research</a>.<b></b></div> <div> </div> <div>The company founders are dr. J.M.H. Raats, prof. dr. W.J. van Venrooij, and dr. G.J.M. Pruijn have extensive experience and an excellent reputation in the field of autoimmune diseases. The founders have successfully developed a new diagnostic target for rheumatoid arthritis (CCP).  In May 2002, Prof. W.J. van Venrooij was awarded the highly prestigious international "Carol Nachman Award" for his outstanding contributions to the autoimmunity field. The company is headed by dr. J.M.H. Raats.<font face="Times New Roman"><span style="COLOR: black; FONT-SIZE: 11pt; mso-ansi-language: EN-GB" lang="EN-GB"> </span></font></div> </font></span> <p> </p> <p> </p> <p style="MARGIN: 0cm 0cm 0pt" dir="ltr" class="MsoNormal" align="justify"><span style="COLOR: black; mso-ansi-language: EN-GB" lang="EN-GB"> </span></p> <p> </p> <p> </p> <p> </p> <p> </p><p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><span><font size="2"><span lang="EN-GB" style="mso-ansi-language: EN-GB"><span lang="EN-GB" style="mso-ansi-language: EN-GB"> <p align="justify"><span lang="EN-GB" style="mso-ansi-language: EN-GB"><span lang="EN-GB" style="mso-ansi-language: EN-GB"><span lang="EN-GB" style="mso-ansi-language: EN-GB"> <p><font face="Verdana">Over the last 15 years there has been considerable interest in the use of biological reagents as therapeutics. In particular the use of therapeutic antibodies has emerged as one of the leading areas for next generation therapeutics for the pharmaceutical industry.</font></p> </span></span></span></p> </span></span></font></span></p> <div>As of January 2009, there are 25 FDA approved therapeutic antibodies approved for clinical use.  In addition, over 200 more are currently in registered clinical trails.  Of the 25 approved therapeutic antibodies approximately 50% are human antibodies with the trend over the last few years being the introduction of more and more human antibodies (rather than murine-based and humanised antibodies). </div> <div> </div> <div>During 2007, revenues from therapeutic monoclonal antibodies were approximately $26 billion.  The biggest selling single therapeutic was Rituxan® accounting for sales of approximately $5 billion. By far the fastest growing therapeutic was Avastin® with a 68% growth between 2006 and 2007 and in 2007 had sales of approximately $4 billion. </div> <div> </div> <div>Of all currently approved therapeutic antibodies 40% are for the treatment of cancer and 35% are for the treatment of auto-immune disease. </div> <div> </div> <div>The time taken from the first discovery of the antibody reagent to a therapy being available for prescription typically ranges from 10-12 years.  However, the recent high profile clinical case in 2006 of TGN1412, intended for auto-immune disease and haematological malignancies, has meant that increased time should now be allowed for Phase I trials. </div> <div> </div> <div>In 2005, there were approximately 30 companies actively pursuing therapeutic antibodies.  Four years later, 14 of these companies have been purchased for their therapeutic pipeline and technology.  As of today there are a dozen or so independent therapeutic antibody companies. </div> <div> </div> <div>What does the future hold for therapeutic antibodies and for companies with a therapeutic antibody pipeline?  Predicting the future is difficult; however, one thing is sure companies will always be looking for a commercial edge.  Where therapeutic antibodies can provide utility for both companies and in treating patients with disease their continued status as the shining lights in the face of the global credit crunch will remain.  </div> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p align="justify"> </p><p><strong>ModiQuest </strong>uses automated <strong>high throughput</strong> cell screening facilities (<strong>ClonePix technology</strong>), combined with very efficient <strong>electro-fusion</strong> and/or <a href="show.php?id=16" target="_self"><strong><u><font color="#810081">proprietary B-cell selection</font></u></strong></a> and culture technology, for <strong>efficient</strong> and <strong>excellent quality hybridoma </strong>generation. </p> <p style="MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="justify"> </p> <p style="MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="center"><img alt="" src="http://www.modiquestresearch.com/website/downloads/Image/clonepixb.JPG"/></p> <p style="MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="justify"> </p> <p style="MARGIN: 0cm 0cm 0pt" class="MsoNormal" align="justify"> </p><div align="justify"><span><span class="BodyText"><font face="Arial"> </font></span></span></div> <div align="justify"><span><span class="BodyText"><font face="Arial"></font></span></span></div> <div align="justify"><span><span class="BodyText"><font face="Arial"><strong>ModiQuest</strong> uses state of the art technologies to develop novel diagnostics and therapeutics:</font></span></span></div> <ul> <li><font face="Arial"><span><span class="BodyText"><strong><a href="http://www.modiquest.com/website/show.php?id=16" target="_self"><u><font color="#810081">Antigen specific B-cell selection and culture</font></u></a></strong></span></span> </font></li> <li><font face="Arial"><span><span class="BodyText"><strong>Antibody cloning from antigen specific B-cells</strong></span></span> </font></li> <li><span><span class="BodyText"><strong><span><span class="BodyText"><strong><font face="Arial">Antibody cloning from hybridomas </font></strong></span></span></strong></span></span></li> <li><font face="Arial"><span><span class="BodyText"><strong><span><span class="BodyText"><strong>Efficient automated <a href="show.php?id=17" target="_self"><u><font color="#0000ff">Hybridoma generation</font></u></a></strong></span></span></strong></span></span> </font><span><span class="BodyText"> <li><font face="Arial"><strong><span><span class="BodyText">Proprietary vectors for expressing recombinant human, and mouse antibodies.</span></span> </strong></font></li> <li><font face="Arial"><strong><span><span class="BodyText"><span><span class="BodyText">Gene synthesis</span></span></span></span> </strong></font> </li> <li><span><span class="BodyText"><strong>Automated </strong><a href="show.php?id=18" target="_self"><font face="Arial" color="#810081"><u><strong>stable (antibody producing) cell line generation</strong></u></font></a></span></span><font face="Arial"><strong> </strong></font></li> <li><span><span class="BodyText"><strong>Proprietary </strong><a href="show.php?id=19" target="_self"><font face="Arial" color="#0000ff"><u><strong>Animal Models for Rheumatoid Arthritis</strong></u></font></a></span></span> </li> <li><span><span class="BodyText"></span></span><a href="show.php?id=20" target="_self"><strong><font face="Arial" color="#0000ff"><u>Proprietary Enzyme Activity Assays</u></font></strong></a><strong>  </strong> </li> </span></span></li> </ul> <p><span><span class="BodyText"><font face="Arial"><strong>ModiQuest is </strong>specialized in the generation of antibodies against difficult targets such as antibodies specific for post-translationally modified (neo) epitopes.<br/> <br/> <strong>ModiQuest </strong>has obtained technology licenses from third parties.</font></span></span></p><p><strong><font size="3">Welcome to project MQ2008029</font></strong></p> <p>Pleae click on file manager in upper right corner to view, up or download files to this project.</p> <p>Please make sure all files are <strong>password</strong> secured.</p> <p>For any additional questions please call or mail the <strong>Modiquest Team.</strong> Please mention or indicate the project number in your phone or email with our team.</p> <p>Phone: +31 (0)24 3614253</p> <p>E-mail: <a href="mailto:info@modiquest.com">info@modiquest.com</a></p> <p> </p><div> <p align="justify"><font face="Arial"><strong>ModiQuest </strong>uses proprietary Antigen Specific B-cell selection, combined with highly efficient </font><font color="#810081" face="Arial"><a href="show.php?id=17" target="_self">hybridoma generation</a></font><font face="Arial"> or direct antibody cDNA cloning from antigen specific B-cells that allow the generation of </font><font color="#810081" face="Arial"><a href="show.php?id=18" target="_self">stable human antibody expressing cell lines</a></font><font face="Arial"><a href="javascript:void(0);/*1205014407609*/">.</a> </font></p> <p align="justify"><font face="Arial">Antigen specific B-cell selection offers a fast and efficient opportunity to obtain (recombinant) antibodies from various species (i.e. mouse, human, llama, chicken, rabbit etc.).</font></p> <p align="justify"><font face="Arial">Difficult and rare antibody specificities can be generated using B-cell panning technology.</font></p> <p align="justify"><font face="Arial">ModiQuest focuses on the generation of animal and human antibodies specific for post-translationally modified (neo) epitopes. </font></p> </div><p align="center"> <img alt="" src="http://www.modiquest.com/website/downloads/Image/tissue3.jpg" align="middle"/></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><font size="3"><strong>Monoclonal antibody Services </strong> <p><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">ModiQuest’ technical staff has a long-term experience in custom antibody production. Our goal is to deliver hybridoma cell lines secreting highly specific monoclonal antibody to our clients.<br/> <br/> </span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Antibody production can be performed using <a class="" href="show.php?id=2" target="_self">ModiQuest’ standard protocols</a> or fully customized according to the customers specifications.</span></p> </font></span></p> <p> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">ModiQuest guarantees full confidentiality regarding the antigens and projects. Generation of hybridoma cell lines and antibody production can be performed under the terms of a secrecy agreement if requested.<br/> <br/> </span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Once hybridoma cell lines are developed, we can produce monoclonal antibodies suitable for various types of standard laboratory assays in a <a class="" href="show.php?id=8" target="_self">small scale bioreactor (CL1000 Integra).</a></span></p><p> <table cellspacing="0" cellpadding="0" width="100%" border="0"> <tbody> <tr> <td><strong>ModiQuest B.V.<br/> </strong> <div style="MARGIN: 0cm 0cm 0pt"><span lang="EN-GB"><font face="Arial"></font></span></div> <div style="MARGIN: 0cm 0cm 0pt"><span lang="EN-GB"><font face="Arial"></font></span></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><em><font face="Arial"></font></em></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><em><font face="Arial"></font></em></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><em><font face="Arial">Visiting address:</font></em></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span class="Code"><font face="Arial">Innovation lab</font> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">Heyendaalseweg 135</font></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">6525 AJ, Nijmegen</font></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">The Netherlands  </font></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"> </font></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"><em>Postal address:</em> </font></div> </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span class="Code"><font face="Arial">Schoutstraat 58 </font> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">6525 XV Nijmegen</font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">The Netherlands</font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"> </font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"></font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><em><font face="Arial">Delivery address:</font></em></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">ModiQuest </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">Logistiek Centrum FNWI </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">Toernooiveld 8 </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">6525 ED </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">Nijmegen </span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: `Times New Roman`; mso-fareast-language: NL; mso-bidi-language: AR-SA; mso-no-proof: yes">The Netherlands</span></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"></font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"></font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"></font></div> </span></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span class="Code"><br/> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">Mobile  +31 (0)6 16940490</font></div> <div style="mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">Phone  +31 (0)24 3614253 </font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">           +31 (0)24 3613658<br/> <span class="Code">Fax      +31 (0)24 3502154                </span></font><span class="Code"></span></div> </span></div> </td> <td valign="top"> <p> <img alt="" src="http://www.modiquestresearch.com/website/downloads/Image/huygens%20gebouw.jpg"/></p> <p> </p> <p> </p> <p> </p> <p> </p> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><span class="Code"> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial"></font></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">E-mail  </font><a href="mailto:Info@modiquest.com"><font face="Arial" color="#0000ff"><u>Info@modiquest.com</u></font></a></div> <div class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; mso-element: frame; mso-element-frame-width: 203.25pt; mso-element-frame-height: 51.1pt; mso-element-frame-vspace: 0cm; mso-element-wrap: no-wrap-beside; mso-element-anchor-horizontal: page; mso-element-left: 386.2pt; mso-element-top: 34.9pt"><font face="Arial">Web    </font><a href="http://www.modiquest.com/" target="_blank"><font face="Arial" color="#0000ff"><u>HTTP://www.modiquest.com/</u></font></a></div> </span></div> </td> </tr> </tbody> </table> <em><font size="2"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"></span></font></em></p> <div> </div><p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"><font face="Times New Roman">Depending on how you arrive in the Netherlands, this is how you can find the city of Nijmegen and the ModiQuest Facilities: </font></font></p> <br/> <strong>Car</strong> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font face="Times New Roman" size="3"><a href="http://www.modiquest.com/website/downloads/download.php?id=43" target="_blank">Map Nijmegen</a>               </font><font face="Times New Roman" size="3"><a href="http://www.modiquest.com/website/downloads/download.php?id=42" target="_blank">Map Campus</a></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"> </font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"><font face="Times New Roman"><u>Parking:</u> </font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"><font face="Times New Roman">All car parks in the vicinity are equipped with barriers and point-of-pay terminals. Regular parking cost € 0.80 per hour and a maximum of € 4 per day.  After 18.00 and during weekends regular parking is free. <p><font size="3"><font face="Times New Roman"><strong>Plane<br/> </strong>If you come to the Netherlands by air, you can take a train from Schiphol Airport to Duivendrecht (there is a train every thirty minutes), where you change trains. There are direct trains to Nijmegen Central Station every thirty minutes. The journey will take an hour and a half in total. <br/> <br/> <strong>Train<br/> </strong>If you are travelling by train (possibly preceded by a boat journey) from your own country, one of the following situations will apply:</font></font></p> <p><font size="3"><font face="Times New Roman">Coming from the south (from Paris, Brussels, etc.), you will have to change trains at the first station in the Netherlands, Roosendaal. You take the inter-city train to Zwolle, and get off in Nijmegen. There is a train every thirty minutes, and the journey will take about an hour and a half </font></font></p> </font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"><font face="Times New Roman"> <p><font size="3"><font face="Times New Roman">Coming by boat from overseas (England, Ireland), you will probably arrive in Hoek van Holland. At Hoek van Holland you should take the train to Rotterdam Central Station, where you change trains for Breda. In Breda, board the train to Nijmegen. The train journey takes between 2 and a half and 3 hours.</font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">Coming from the southeast (Germany, Italy, Switzerland, Austria, etc.), the train will take you through Germany along the Rhine until you arrive in Arnhem. Trains between Arnhem and Nijmegen run every 10-15 minutes. It only takes a quarter of an hour to get from Arnhem to Nijmegen</font></font></font></font></p> </font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">Coming from the east (northern Germany, Denmark, boat-trains from Scandinavia, Poland, the New Independent States, etc.), the trains’ itinerary will include cities such as Hanover in Germany. Hengelo is the first station in the Netherlands. Do not get off there, but continue for half an hour until you get to Zutphen, where you change trains for Nijmegen. You should arrive in Nijmegen after approximately 40 minutes.</font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font face="Times New Roman" size="3">When travelling by train (</font><a title="www.ns.nl" href="http://www.ns.nl/" target="_blank"><u><font face="Times New Roman" color="#0000ff" size="3">www.ns.nl</font></u></a><font size="3"><font face="Times New Roman">), keep three things in mind: </font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">1. Always check at the railway station (or if possible at home) if the scheme mentioned above is still correct. </font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">2. In the Netherlands, trains do not run all night. If you arrive on a very late international train, it is possible that you will not make it to Nijmegen that day. The latest possible arrival time ranges between 0.30 and 1.30 A.M.</font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">3. Do not buy a ticket every time you change trains. In most cases you will be able to buy a ticket to Nijmegen in your hometown. If this is not the case, buy a ticket to Nijmegen at the first station in the Netherlands you enter, regardless of how many times you may have to change trains. This will save you much time (and money). <br/> <br/> <strong>Train tickets and Pass Types</strong> </font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">1. Singles and Day Returns (Enkele reis en Dagretour). It is cheaper to buy a Cheap Day Return than two singles. Your return journey must take place on the same day. </font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">2. Day Travel Card (Dagkaart). This card allows you unlimited travel around the country in the space of one day. For € 4.50 extra, you can use other forms of public transport too, such as the bus, metro, or tram (this is called an OV Dagkaart). </font></font></font></font></p> <p><font size="3"><font face="Times New Roman"><strong>Prices</strong><br/> - Day Travel Card 2nd class € 37.10 <br/> - Day Travel Card 1st class € 59.40 <p><font size="3"><font face="Times New Roman">3. Weekend Return (Weekendretour). A Weekend Return is the same as a Day Return, except that it is valid for a whole weekend. For the price of a day return you can make your journey between 7 P.M. Friday evening and 4 A.M. the following Monday morning. <p><font size="3"><font face="Times New Roman">4. Holland Rail Pass. This pass gives you unlimited access to all railways nation-wide for either three or five days, depending on the arrangement. You do not have to travel on consecutive days, but you must use your travel days within the period of one month. The Holland Rail Pass is available at railway ticket offices or at NS sales outlets abroad, upon presentation of your passport. <p><font size="3"><font face="Times New Roman">5. The Off-peak Discount Pass (Voordeel-urenkaart). If you travel after 9 A.M. Monday to Friday or on weekends, the Off-Peak Discount Pass (€ 49.00) enables you to travel within the Netherlands at a 40% discount. Off-Peak Discount Pass holders can travel with up to three people, who can enjoy the same 40% discount on the full fare. To obtain an Off-Peak Discount Pass, you must bring a passport photo (and the required amount of money) to the railway station ticket window, where you will fill out an application. After approx. three weeks you will receive the card at your home address.</font></font></p> <p><font size="3"></font><font size="3"><font face="Times New Roman"><br/> Once you have arrived at Nijmegen Central Station, the easiest way to get to the ModiQuest facilities is by bus. It takes you 7 minutes to get to the ModiQuest facilities: <p><font size="3"><font face="Times New Roman">number 10 (Heyendaal shuttle) runs every 7 minutes. </font></font></p> </font></font></p> </font></font></p> </font></font></p> </font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt" align="justify"><font size="3"><font face="Times New Roman"> <p><font size="3"><font face="Times New Roman">Get of at the HAN stop at the Kapittelweg, opposite of the Trigon building where ModiQuest B.V. is situated.</font></font></p> <p><font size="3"><font face="Times New Roman"><font size="3"><font face="Times New Roman">`Strippenkaarten` are valid all over the Netherlands and can be used on any bus, tram or metro in the country. Strippenkaarten can be bought at the bus, tram or metro station, but the cheapest places to buy them are at the post office and the train station. On most buses it is the bus driver who stamps your ticket. Trams and some buses have devices that enable you to stamp the ticket yourself. Before you stamp your ticket, you need to know how many zones you will be crossing. Zone information is given on the information panels at bus, metro and tram stops.</font></font></font></font></p> </font></font></p><p><span lang="EN-GB" style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><span style="mso-spacerun: yes"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><font size="3"><strong>ModiQuest provides polyclonal Rabbit antibody services</strong></font></span>  <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong><br/> Standard polyclonal rabbit antibody protocol:</strong></span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">(80 days, <span lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-US">€ 10</span>00)</span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"></span> </p> <span style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"> <ul style="MARGIN-TOP: 0cm" type="disc"> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The polyclonal antibody protocol starts with obtaining a pre-immune blood sample of two New Zeeland White rabbits </span></li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The primary immusation if performed with the, by the client provided, purified antigen<sup>1</sup> emulsified with Complete Freund’s Adjuvant (CFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 14 days, the rabbits receive a second injection of the antigen with Incomplete Freund’s Adjuvant (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 28 days, the rabbits receive a third injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">After 56 days, the rabbits receive a fourth injection of the antigen with (IFA)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The first blood sample is obtained 14 days after the fourth injection  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The polyclonal serum samples are screened by ELISA to determine the comparative titres of antigen-specific antibody. (Alternatively, the serum samples can be shipped<sup>2</sup> to the client for screening with a different assay, or ModiQuest can perform customized assays according to the clients’ specifications<sup>3</sup>)  </span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">The animals with good responses are anesthetized and terminated by exsanguination. Alternatively another round of immunizations and a second bleed<sup>4</sup> can be performed on all animals. Following a second serum assay the client decides whether the animals are anesthetized and terminated by exsanguination</span> </li> <li class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Polyclonal serum samples are shipped to the client</span> </li> </ul> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB">Above immunisation protocol can be customized according to the clients specifications, and/or combined with the <a class="" href="show.php?id=6" target="_self">peptide antigen design</a> and/or <a class="" href="show.php?id=6" target="_self">affinity purification</a> protocols</span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span> </p> <span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"></span><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l1 level1 lfo1; tab-stops: list 36.0pt"><font color="#800080">Payment for the <b style="mso-bidi-font-weight: normal">polyclonal rabbit antibody services </b>should be received before the project is initiated. <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang="EN-GB" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"><br/> <font color="#000000">All shipments from ModiQuest will be shipped on dry ice. The fee for this service will be charged to the client.</font></span></p> </font></p> <p> </p> <p> </p> </span></span></span></span></p> <p> </p> <p> </p><p class="MsoNormal" style="MARGIN: 0cm 0cm 10.8pt; LINE-HEIGHT: 17.4pt; mso-line-height-rule: exactly"><font face="Times New Roman"><b><span lang="EN-US" style="FONT-SIZE: 20pt; mso-ansi-language: EN-US">ModiQuest:</span></b><span lang="EN-US" style="FONT-SIZE: 13pt; mso-ansi-language: EN-US; mso-bidi-font-size: 10.0pt"> </span></font><font face="Times New Roman"><span lang="EN-US" style="FONT-SIZE: 14pt; mso-ansi-language: EN-US">new targets and tools </span><span lang="EN-US" style="FONT-SIZE: 11pt; mso-ansi-language: EN-US">for</span><span lang="EN-US" style="FONT-SIZE: 14pt; mso-ansi-language: EN-US"> diagnostics and therapeutics<br/> </span></font><font face="Times New Roman"><span lang="EN-US" style="FONT-SIZE: 14pt; mso-ansi-language: EN-US"><i style="mso-bidi-font-style: normal"><span style="LETTER-SPACING: 0.3pt"></span></i></span></font></p> <p> </p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 7.2pt"><b style="mso-bidi-font-weight: normal"><span lang="EN-US" style="FONT-SIZE: 13pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-US; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: `Times New Roman`">COLLABORATIVE RESEARCH TO COMBAT RHEUMATOID ARTHRITIS</span></b></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes"><span style="FONT-FAMILY: Arial; mso-no-proof: yes">ModiQuest has entered into a research collaboration dedicated to the development of novel therapeutics to combat rheumatoid arthritis (RA). </span></span></span></span></span></span>This progressive autoimmune disease leads to chronic inflammation and affects about one percent of the world`s population. </span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">ModiQuest will coordinate an extensive research program, aimed at the discovery of inhibitors of so-called PAD enzymes (peptidyl arginine deiminases), in which next to ModiQuest, two research groups from the Radboud University Nijmegen, a research group from the Leiden University Medical Center, and the fellow Dutch company Chiralix participate. Earlier research by the collaborators has identified the pivotal role of this class of enzymes in the onset and progression of RA. The consortium of these five partners has the necessary expertise to study each individual aspect of the complex project in great detail. <br/> </span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">ModiQuest, together with the research group of Dr. Ger Pruijn (Radboud University Nijmegen), will focus on the unraveling of biochemical aspects related to inflammatory processes that occur during rheumatoid arthritis. During these processes proteins are being modified and patients make antibodies against such modified proteins. </span><span style="FONT-FAMILY: Arial; mso-no-proof: yes">Only in rheumatoid arthritis patients antibodies recognizing citrullinated proteins do occur. </span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">The citrullination of proteins is mediated by PAD enzymes, which only become activated when cells die. In rheumatoid arthritis inflammatory events in the joints of patients cause a chain reaction of protein citrullination by PAD enzymes followed by the generation of more antibodies that cause more inflammation resulting in more release of PAD enzymes leading to more citrullination and emerging into a chronic disease. </span><span style="FONT-FAMILY: Arial; mso-no-proof: yes">The most promising class of PAD enzyme inhibitors are oligopeptides. These peptides should be functionalized in such a way that they are able to bind the active site of PAD, thereby blocking the enzyme from performing its natural function. To this end, amino acid building blocks are required, containing specific functionalities in the side chains. </span><span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">Chiralix,<span style="mso-spacerun: yes">  </span>together with a team of researchers headed by Prof. Floris Rutjes (Radboud University Nijmegen) will explore the preparation of the amino acid-based compounds and derivatives. Synthetic oligopeptides containing these compounds will be synthesized by the group of Dr. Jan-Wouter Drijfhout (</span> <place></place> <placename></placename> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">Leiden</span> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes"></span> <placetype></placetype> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">University</span> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes"></span> <placename></placename> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">Medical</span> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes"></span> <placetype></placetype> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">Center</span> <span lang="EN-GB" style="FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-no-proof: yes">). Finally, ModiQuest, who is specialized in the identification of antibodies, new animal models and new targets for autoimmune diagnostics, together with the research group of Dr. Ger Pruijn (Radboud University Nijmegen), will test the compounds and peptides in vitro as well as in vivo.<br/> </span><span lang="EN-US" style="FONT-FAMILY: Arial; mso-ansi-language: EN-US; mso-no-proof: yes"><span lang="EN-US" style="FONT-FAMILY: Arial; mso-ansi-language: EN-US; mso-no-proof: yes"><span lang="EN-US" style="FONT-FAMILY: Arial; mso-ansi-language: EN-US; mso-no-proof: yes"><font color="#000000">The Dutch Ministry of Economic Affairs (SenterNovem) recently provided a grant of two million euros to support this project. <br/> <br/> </font></span> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><span lang="EN-US" style="FONT-SIZE: 9pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`"><font face="Arial"><font size="2">For more information:<br/> <br/> </font></font></span></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><font face="Arial"><font size="2"><span lang="FR" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: FR; mso-bidi-font-family: `Times New Roman`">Dr. Jos Raats, ModiQuest B.V., tel.: +31 24 361 4253, </span><span lang="FR" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: FR; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes">e-mail: </span><span lang="EN-US" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes"><a href="mailto:jraats@modiquest.com"><span lang="FR" style="LETTER-SPACING: 0.1pt; mso-ansi-language: FR; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt"><u><font color="#0000ff">jraats@modiquest.com</font></u></span></a></span><span lang="FR" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: FR; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes"> <br/> <br/> </span></font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><font face="Arial"><font size="2"><span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Dr. Richard Blaauw, Chiralix B.V., tel.: +31 24 365 2194, </span><span lang="EN-US" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes">e-mail: <a href="mailto:richard.blaauw@chiralix.com"><span style="LETTER-SPACING: 0.1pt; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt"><u><font color="#0000ff">richard.blaauw@chiralix.com</font></u></span></a> <br/> <br/> </span></font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><font face="Arial"><font size="2"><span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Prof. Floris Rutjes, Radboud University Nijmegen, Institute for Molecules and Materials, tel.: +31 24 365 3202, </span><span lang="EN-US" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes">e-mail: <a href="mailto:f.rutjes@science.ru.nl"><span style="LETTER-SPACING: 0.1pt; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt"><u><font color="#0000ff">f.rutjes@science.ru.nl</font></u></span></a> <br/> <br/> </span></font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><font face="Arial"><font size="2"><span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Dr. Ger Pruijn, Radboud University Nijmegen, Nijmegen Centre for Molecular Life Sciences, tel.: +31 24 361 6847, </span><span lang="EN-US" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">e-mail: <span style="mso-no-proof: yes"><a href="mailto:g.pruijn@ncmls.ru.nl"><u><font color="#0000ff"><span style="LETTER-SPACING: 0.1pt; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt">g.pruijn</span><span style="LETTER-SPACING: 0.1pt; mso-no-proof: no; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt">@</span></font></u></a><a href="mailto:g.pruijn@ncmls.ru.nl"><span style="LETTER-SPACING: 0.1pt; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt"><u><font color="#0000ff">ncmls.ru.nl</font></u></span></a></span> <br/> <br/> </span></font></font></p> <p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt"><font face="Arial"><font size="2"><span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Dr. Jan-Wouter Drijfhout, </span> <place></place> <placename></placename> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Leiden</span> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`"></span> <placetype></placetype> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">University</span> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`"></span> <placename></placename> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Medical</span> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`"></span> <placetype></placetype> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">Center</span> <span lang="EN-US" style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`">, Department of Immunohaematology and Blood Transfusion, tel.; +31 71 526 1737, </span><span lang="EN-US" style="FONT-SIZE: 8pt; COLOR: blue; FONT-FAMILY: Tahoma; LETTER-SPACING: 0.1pt; mso-ansi-language: EN-US; mso-bidi-font-family: `Times New Roman`; mso-no-proof: yes">e-mail: <a href="mailto:j.w.drijfhout@lumc.nl"><span style="LETTER-SPACING: 0.1pt; mso-ascii-font-family: Tahoma; mso-hansi-font-family: Tahoma; mso-ansi-font-size: 8.0pt"><u><font color="#0000ff">j.w.drijfhout@lumc.nl</font></u></span></a></span></font></font></p> </span></span></p> <p> </p> >